Medical Drug Policy Name | Revised Criteria |
|---|---|
| Antiemetic Injection Therapy Notification | Added newly approved Focinvez (fosaprepitant) to policy, and associated dosing and HCPCS codes C9399, J3490, J3590, and J9999 to FDA label reference table. Adjusted trial and failure requirements for Cinvanti to require trial of Emend (fosaprepitant), and trial of granisetron or ondansetron for low to minimally emetogenic cancer chemotherapy regimens. Adjusted indication for Emend per FDA label to include pediatric patients 6 months of age or older weighing at least 6 kg. Updated NCCN Emetogenic Potential of Intravenous and Oral Antineoplastic Agents tables. Medical policy formatting change. Policy notification given 1/29/2024 for effective date 3/29/2024. |
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2025 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.